Reported about 10 hours ago
AstraZeneca is in negotiations with Summit Therapeutics for a potential licensing agreement for an experimental lung cancer drug worth up to $15 billion. This deal, reported by Bloomberg, could include substantial upfront payments and milestones, although talks may still fall through. The drug, ivonescimab, is already approved in China and is being tested for further use in the U.S.
Source: YAHOO